

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)



(10) International Publication Number
WO 2022/074152 A1

(51) International Patent Classification:

A61K 47/54 (2017.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61K 47/59 (2017.01) C07K 16/32 (2006.01)
A61K 47/60 (2017.01) C12N 15/117 (2010.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))

(21) International Application Number:

PCT/EP2021/077777

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

07 October 2021 (07.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

20200835.5 08 October 2020 (08.10.2020) EP

(71) Applicant: TARGIMMUNE THERAPEUTICS AG
[CH/CH]; Hochbergerstrasse 60c, 4057 Basel (CH).

(72) Inventors: POMBO-VILLAR, Esteban; Höhenweg 63,
4102 Binningen (CH). KITAS, Eric; Eichbergweg 4, 4147
Aesch (CH). ZIGLER, Maya; Hirzbodenweg 17, 4052
Basel (CH). BAJIC, Davor; Beim Letzturm 16, 4052 Basel
(CH). SCHADE, Babette; Gribschweg 5, 6403 Kißnacht
am Rigi (CH). BROKA, Derrick; Zürichstrasse 7, 6004
Luzern (CH).

(74) Agent: SPERRLE, Martin; Latscha Schöllhorn Partner
AG, Grellingerstrasse 60, 4052 Basel (CH).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: IMMUNOTHERAPY FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention relates to a kit-of-parts comprising and a composition comprising a polypeptide comprising a double stranded RNA (dsRNA) and a polymeric conjugate comprising a polyethyleneimine (PEI), one or more polyethylene glycol (PEG) moieties and one or more targeting moieties, and wherein each of said one or more targeting moieties is capable of binding to PSMA; and at least one least one immune checkpoint modulator, wherein said at least one least one immune checkpoint modulator is capable of modulating an immune checkpoint protein. Further the invention relates to this composition or kit-of-parts for use in the treatment of cancer.

WO 2022/074152 A1